ARS Pharmaceuticals (SPRY) announced the launch of the neffyinSchools program. neffyinSchools provides eligible public and private K-12 schools in the U.S. with the opportunity to receive two cartons of neffy 2 mg for use in emergency situations at no cost to the school via the School Health Corp. SHConnect platform. neffy 2 mg is approved for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh greater than or equal to30 kg. Participating schools will be eligible to receive replacement doses when the product is used or expires.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- ARS Pharmaceuticals price target raised to $28 from $26 at Raymond James
- ARS Pharmaceuticals Highlights Success and Plans for 2025
- ARS Pharmaceuticals reports 2025 key strategic priorities
- ARS Pharmaceuticals reports preliminary Q4 neffy revenue $6.5M
- ARS Pharmaceuticals files for approval of neffy in Canada, U.K.